Fexmid (Cyclobenzaprine Hydrochloride)

Fexmid (Cyclobenzaprine Hydrochloride) represents a prescription brand-name muscle relaxant entry registered by Rising Pharma Holdings, Inc. with package codes 64980-705. Reviewed against 2025-04-07 FDA SPL standards (7.5 mg/1 Tablet; 10mg Tablet), clinical deployment addresses Fexmid ® is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute,.

Fexmid achieves therapeutic action via Cyclobenzaprine Hydrochloride, engaging muscle relaxant physiological pathways with class-characteristic hepatorenal disposition. Manufactured in 7.5 mg/1 Tablet; 10mg Tablet (registered by Rising Pharma Holdings, Inc., NDC 64980-705), pharmacists evaluate FDA Orange Book therapeutic equivalence when comparing branded Fexmid ($68.37 retail) with generic Cyclobenzaprine Hydrochloride ($25.80 low cash).

With Steady-state plasma equilibrium reached over 6–10 hour t½ intervals for Fexmid (Cyclobenzaprine Hydrochloride) residence kinetics and Approximately 60% to 72% enteral uptake across labeled Fexmid (Cyclobenzaprine Hydrochloride) strengths bioavailability, Fexmid (Cyclobenzaprine Hydrochloride) undergoes predominantly hepatic biotransformation with renal elimination of polar fexmid (cyclobenzaprine hydrochloride) conjugates and establishes therapeutic activity over maximum serum exposure occurs 2–5 hours after fexmid (cyclobenzaprine hydrochloride) dosing.

Standard adult regimens span 7.5 mg/1 Tablet, 10mg Tablet, 5mg Tablet, 7.5mg Tablet. Prescribers screen specifically against contraindicated in patients with prior serious allergic response to fexmid (cyclobenzaprine hydrochloride) (ndc 64980-705); severe baseline organ impairment where cyclobenzaprine hydrochloride accumulation exceeds safe therapeutic margins, while community micro-logs most frequently note somnolence (29% of reports), nausea (8.7% of reports), dry mouth (8.1% of reports).